lly q4 - Search News

Eli Lilly's Q4 2024 Earnings

Investing · 19h

Eli Lilly: BofA says buy the dip after shares slide on Q4 miss

BofA maintained LLY at Buy and a price target of $997.0, but said it was reviewing its estimates on the stock.

bovnews · 1d

Eli Lilly’s (LLY) Q4 Earnings Fall Short: What’s Next for the Pharma Giant?

Eli Lilly and Company (NYSE: LLY) found itself in the spotlight after its stock plummeted 7.67%, or $61.14, dropping to $736.34 at 12:38 PM EST. With a trading volume of 6.66 million shares—far exceeding the average of 3.

Business Insider · 7h

Eli Lilly Q4 miss brings buying opportunity, says JPMorgan

JPMorgan analyst Chris Schott says Eli Lilly’s Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidanc

Seeking Alpha on MSN · 1d

Eli Lilly issues Q4 2024 revenue guidance below consensus

Eli Lilly and Company (NYSE:LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B, about $400M below the lower end of its recently issued financial guidance.

Barchart on MSN · 2d

Eli Lilly's Q4 2024 Earnings: What to Expect

Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and delivering life-changing medicines to address some of the world's most pressing medical needs.

Zacks.com on MSN6h

LLY Stock Down on Lower-Than-Expected Sales Guidance for Q4

LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates ...

Hosted on MSN5h

Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish

Eli Lilly & Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6% plunge — the worst ...

Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks

Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, ...

20h

Eli Lilly & Co: Strong Long-Term Growth Prospects Amid Q4 Revenue Shortfall Justify Buy Rating

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price ...

Hosted on MSN2h

Eli Lilly Cuts Q4 Sales Forecast: ETFs to Buy on the Dip

Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight-loss ...

1don MSN

Hims & Hers in focus as Eli Lilly obesity drug sales disappoint

Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...

Insider Monkey1d

Why Eli Lilly (LLY) Stock Is Declining Today

The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company preannounced lower-than-expected ...

Finbold | Finance in Bold7h

Here’s why Eli Lilly stock is crashing

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Lilly Cuts Q4 Revenue View Below Market, Lifts FY24 Outlook; Sees Growth In FY25

Drug major Eli Lilly and Co. (LLY) on Tuesday trimmed its fourth-quarter revenue view below the Street estimates, but raised forecast ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results